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Editorial summary
Failure to consider lessons from behavioral economics
in the case of whole genome sequencing may cause
us to run into the ‘last mile problem’ - the failure to
integrate newly developed technology, on which
billions of dollars have been invested, into society
in a way that improves human behavior and
decision-making.
Much energy and other resources are being invested in
efforts to integrate whole genome sequencing (WGS)
and whole exome sequencing (WES) into clinical care.
For example, the National institutes of Health (NIH)
plans to invest $400 million into translational genomic
projects over the next few years. Already, millions of
dollars have been committed to exploring the clinical in-
tegration of genomics through programs such as the
Clinical Sequencing Exploratory Research (CSER) Consor-
tium. This consortium funds nine centers to study the gen-
eration of genomic sequence data, methods to translate and
interpret those data, and the ethics and psychosocial impact
of those data in a variety of pediatric and adult clinical set-
tings. As members of one of the funded centers, we are op-
timistic about the future of clinical genomics. Nevertheless,
in addition to well-recognized technical and translational
challenges that are associated with the clinical integration
of WGS or WES, the field of behavioral economics suggests
that there will be equally daunting behavioral challenges.
Behavioral economics is a field of study which empha-
sizes that provision of information does not necessarily
lead to rational use of information. Failure to consider
lessons from behavioral economics in the case of WGS
or WES may cause us to run into what economist
Sendhil Mullainathan calls ‘the last mile problem’ [1].
This is the investment of billions of dollars in resources
* Correspondence: jsswinde@bcm.edu
1Center for Medical Ethics and Health Policy, Baylor College of Medicine, One
Baylor Plaza MS 420, Houston, TX 77030, USA
Full list of author information is available at the end of the article
to develop new technology, but the failure to integrate
that technology into society in a way that improves hu-
man behavior and decision making. The aim of this
comment is to outline how several cognitive biases that
are well-studied in behavioral economics - information-
seeking bias, affect bias, and impact bias - might impede
the successful integration of WGS and WES into clinical
care and to suggest strategies for mitigating them. In
doing so, we highlight the importance of considering these
issues as part of ongoing research. To our knowledge, our
group is the only project explicitly examining behavioral
economics issues and their impact on translational gen-
omic research. We believe that these considerations will
be integral to the success of clinical genomics.
Information-seeking bias and defaults
One potential example of the last mile problem can be
found in a phenomenon that behavioral economists call
‘information-seeking bias’ - the tendency people have to
seek information even if that information lacks utility or
meaning. In the context of genetic testing, surveys show
that many people report that they want all genetic re-
sults returned, even if the meaning of those results is
unknown [2]. It has been suggested that disclosing ‘all of
the information’, even when much of it is ambiguous,
could lead to wasted healthcare resources and iatrogenic
harms if additional diagnostic tests or procedures were
pursued. In our own study (the MedSeq Project) [3], we
have found patients who expressed intentions to deal
with any ambiguous genetic information by seeking
second opinions and referrals to other clinicians. The
collection of post-disclosure data to examine patients’
actual behaviors regarding second opinions and referrals
is ongoing. At 6-months follow-up, 6 of 18 participants
have reported sharing their genetic information (disclosed
by their doctor) with another doctor (ALM, JBB, PU and
RG, unpublished data).
To help mitigate information-seeking bias and its
effects in genomic medicine, clinicians could decide to pro-
vide patients with a specific information set (for example,
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the ‘default’, while allowing patients to opt out if they want
more extensive results returned. For our clinical sequencing
exploratory research study (the MedSeq Project), participat-
ing genetics experts judged that the default set of results
returned should include information about: (1) high-
penetrance disease mutations (such as those related to
hypertrophic cardiomyopathy), (2) disease-risk alleles (for
example, variants for prostate cancer or venous thrombo-
embolism), (3) their carrier status for highly penetrant re-
cessive diseases (such as cystic fibrosis and Tay-Sachs
disease), and (4) pharmacogenomic traits (such as an in-
creased sensitivity to warfarin). Other experts may come to
different judgments. But even this preliminary judgment
raises two important issues. First, some patients may per-
ceive this approach to be overly paternalistic. Yet, under
this approach, patients remain free to receive the informa-
tion they desire while being more likely to focus on the
most relevant information. Numerous studies in behavioral
economics have demonstrated the power of defaults in im-
proving people’s decisions [4]. Second, the use of defaults
raises the challenge of deciding what to include in the de-
fault group of results. In part, this challenge can be met
through a fair and multi-stakeholder process, as is often the
case with the establishment of best-practice standards sur-
rounding contentious issues.
Affect bias and contextualization of risk
Another important behavioral economics concept rele-
vant to WGS and WES integration is the ‘affect bias’, the
finding that risk perceptions and related behaviors
are influenced more by people’s emotional response to
risk than by their cognitive evaluation of that risk [5].
Emotional responses to risk such as fear and anxiety are
often influenced less by the magnitude of the risk (for
example, 1 in 10,000 versus 1 in 100,000) than by the
nature of the risk itself (for example, an elevated cancer
risk might provoke an especially strong response) [5].
WGS and WES will deliver a lot of information to pa-
tients about their health risks, and patients may demon-
strate oversensitivity to information on the possibility of
developing diseases that is not tempered by the associ-
ated probability of disease occurrence [5]. This could be
compounded by the inaccurate perception that all gen-
etic risks are deterministic.
In many settings, it will be crucial to counter these
reactions by contextualizing and framing genetic risk
information for patients. Behavioral economists have
found that response to risk information can be im-
proved by using various contextualization techniques
[6]. Contextualization of risk includes giving patients
comparative risk information in addition to informa-
tion on absolute risk. For example, patients could also
be told of competing risks that they would face over
the next five years and/or the genetic risk of most
other people [6]. Additional methods include present-
ing risk information in both positive and negative
frames and using pictographs to make risk statistics
easier to interpret [6].
Impact bias and behavior-change techniques
An additional behavioral economics concept that is
relevant to the clinical integration of WGS and WES
is the tendency that people have to inaccurately pre-
dict how health conditions or test results will affect
their lives. This results from an ‘impact bias’ whereby
people overestimate the intensity and duration of
emotions brought on by new circumstances [7]. In the
context of WGS or WES, patients may seek genetic
testing out of a belief that the information will help
motivate them to pursue healthier behaviors, predict-
ing that learning about an elevated risk of heart dis-
ease, for example, will spur them on to exercise or to
go to the doctor for check-ups more regularly. But pa-
tients might overestimate the intensity and duration of
positive motivational states that are associated with
their results. Caulfield and colleagues [8] have linked
this to the ‘rhetoric of patient empowerment’ in WGS
and WES, noting that there is little evidence to sup-
port the premise that patients will use genetic-risk
information to improve their lifestyle and reduce their
disease susceptibility.
The effects of the impact bias can be countered by
taking care to combine the reporting of WGS or WES
information with techniques known to promote longer-
lasting behavioral change. Behavioral economics has
identified several effective ways to help people follow
through on their behavioral intentions. For instance, cli-
nicians can utilize the ‘present bias’ by offering small
and immediate payments for beneficial behaviors such
as smoking cessation, medication adherence or weight
loss [9]. In addition, clinicians may be able to overcome
the short-lived nature of this motivation by coupling dis-
cussion of WGS or WES results with techniques that
utilize the desire to follow through with promises and
commitments to others. These and other techniques
(along with associated ethical considerations) have been
outlined elsewhere [10].
The suggestion that behavior changes that are based
on WGS or WES risk information should be prescribed
or even incentivized may engender concerns about the
appropriateness of such practice, given that thousands of
common variants provide only modest risk information
(typically with relative risk of less than 2.0) [9]. But the
ends of behavior change prescriptions to stop smoking,
to exercise and to eat healthier are valuable for all
patients, regardless of risk, and they are also, in many
cases, goals articulated by the patient.
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Understanding human behavior is key to successfully in-
tegrating WGS and WES into clinical medicine. Behav-
ioral economics provides us with insights into the less
than optimal ways that patients may respond to their
WGS or WES information, but it also provides us with
insights into how to minimize these suboptimal reac-
tions and how to maximize the positive ways patients
can use this information to improve their lives. Funded
research should focus on studying these issues and solu-
tions explicitly. Currently funded projects should analyze
their data (including audio tapes of disclosure visits,
follow-up interviews or surveys with patients who re-
ceived their WGS or WES results) with an eye to these
issues. Future funded research projects should study the
effectiveness of strategies to mitigate some of these ef-
fects. Without this focus, we risk abandoning the effort
to implement genomic medicine before completing the
last mile.
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